Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 2012. The report details a specific share repurchase transaction executed on September 7, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,733,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,430.0 pence per share; lowest price paid was 1,405.0 pence per share.
- Treasury Holdings (Settled): 506,282,427 shares, representing 9.25% of total issued share capital.
- Treasury Holdings (Including Unsettled): 511,215,427 shares, representing 10.29% of current total voting rights.
- Shares in Issue (Excluding Treasury): 4,966,061,498 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,733,000 shares for Treasury. Consequently, the percentage of shares held in Treasury increased to 9.25% of issued capital (or 10.29% of voting rights including unsettled shares). The filing does not provide comparative data for prior periods regarding these specific metrics.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total cost of the 1,733,000 shares purchased (not explicitly stated in the text).
- Confirm the settlement status of the 4,933,000 shares included in the "including unsettled" treasury count.
- Review the remaining authorization limit for share buybacks under the May 3, 2012 shareholder mandate.
- Check subsequent filings for the impact of this buyback on earnings per share (EPS) calculations.